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Mu and Delta opioid receptors activate the same G proteins in
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1 There is evidence for interactions between mu and delta opioid systems both in vitro and in vivo.
This work examines the hypothesis that interaction between these two receptors can occur
intracellularly at the level of G protein in human neuroblastoma SH-SY5Y cells.
2 The [35S]GTPgS binding assay was used to measure G protein activation following agonist
occupation of opioid receptors. The agonists DAMGO (EC50, 45 nM) and SNC80 (EC50, 32 nM)
were found to be completely selective for stimulation of [35S]-GTPgS binding through mu and delta
opioid receptors respectively. Maximal stimulation of [35S]-GTPgS binding produced by SNC80 was
57% of that seen with DAMGO. When combined with a maximally eective concentration of
DAMGO, SNC80 caused no additional [35S]-GTPgS binding. This eect was also seen when
measured at the level of adenylyl cyclase.
3 Receptor activation increased the dissociation of pre-bound [35S]-GTPgS. In addition, the delta
agonist SNC80 promoted the dissociation of [35S]-GTPgS from G proteins initially labelled using the
mu agonist DAMGO. Conversely, DAMGO promoted the dissociation of [35S]-GTPgS from G
proteins initially labelled using SNC80.
4 Tolerance to DAMGO and SNC80 in membranes from cells exposed to agonist for 18 h was
homologous and there was no evidence for alteration in G protein activity.
5 The ®ndings support the hypothesis that mu- and delta-opioid receptors share a common G
protein pool, possibly through a close organization of the two receptors and G protein at the plasma
membrane.
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Opioid mu and delta receptors couple to pertussis toxin
sensitive G proteins (Uhl et al., 1993), which inhibit adenylyl
cyclase. Selective agonists at the mu and delta receptors have
their own distinct characteristics and pharmacology, though
there is evidence for cross-talk between the two receptor
types. This comes from ligand binding assays and pharma-
cological assays including antinociception, bladder contrac-
tion, antitussive activity and inhibition of gut propulsion (for
review see Traynor & Elliott, 1993), although cross-talk is not
apparent in isolated tissue preparations (Elliott & Traynor,
1995; Matthes et al., 1998). In addition, there is evidence of a
role for the delta opioid system in the development of
tolerance to mu-opioid agonists (Abdelhamid et al., 1991;
Kest et al., 1996; Hepburn et al., 1997).
More recently these interactions have been highlighted with
the availability of opioid receptor knockout mice. Delta
analgesia and respiratory depression are reported to be
reduced in mu-receptor knockout mice (Matthes et al., 1998)
and there is con®rmation of a role for the delta system in mu-
tolerance from studies with delta-receptor knockout mice
(Zhu et al., 1999). Finally, there is evidence for the presence
of mu-/ delta-receptor interactions when both receptors are
co-expressed in GH3 cells (Martin & Prather, 2001) and
evidence for hetero -dimers or -oligomers when both
receptors are expressed in COS-7 (George et al., 2000) or
HEK-293 (Gomes et al., 2000) cells, resulting in receptors
with dierent ligand binding and functional properties.
Intracellular cross-talk mechanisms between receptors
could occur at the level of G protein (Kenakin & Morgan,
1989). For example, in membranes from turkey erythrocytes
and rat adipocytes dierent Gs-coupled receptors share a
common G protein pool (Pike & Lefkowitz, 1981; Murayama
& Ui, 1984), and in hamster adipocyctes dierent Gi-coupled
receptors can access the same G proteins (Murayama & Ui,
1984). Both mu- and delta-opioid receptors couple to similar
subtypes of Gi and Go proteins which inhibit adenylyl cyclase
and are pertussis-toxin sensitive (Laugwitz et al., 1993;
Chakrabarti et al., 1995; Prather et al., 1994a). This study
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was designed to test the hypothesis that mu and delta
receptors activate the same individual G proteins in cells that
express both receptor types and this provides a focus for
interaction. Human neuroblastoma SH-SY5Y cells were
chosen for this study because they endogenously express
both mu- and delta-opioid receptors (Kazmi & Mishra, 1987)
that couple to similar eectors. For example, in SH-SY5Y
cells agonist occupation of both receptor types leads to
inhibition of adenylyl cyclase and, in dierentiated SH-SY5Y
cells, inhibition of o-conotoxin-sensitive Ca2+ channels
(Toselli et al., 1997) and mobilization of Ca2+ from
intracellular stores (Connor & Henderson, 1996).
Opioid-receptor-mediated activation of G proteins stimu-
lates the binding of [35S]-GTPgS to G proteins in SH-SY5Y
membranes (Traynor & Nahorski, 1995). Agonist stimula-
tion of [35S]-GTPgS binding is dependent on the presence of
GDP which binds to unoccupied G protein. Receptor
activation leads to a conformational change in G protein
that decreases its anity for nucleotide, causing the
dissociation of GDP which subsequently allows [35S]-GTPgS
to bind, although the anity of [35S]-GTPgS is also reduced.
However, receptor stimulation by agonist also leads to an
increased dissociation of [35S]-GTPgS which is already bound
to the G protein, provided the receptor has access to the
[35S]-GTPgS-bound Ga subunit. Such an eect has been
demonstrated in both the muscarinic acetylcholine (Hilf et
al., 1992) and cannabinoid (Breivogel et al., 1998) G
protein-coupled receptor systems. Therefore, receptor-
mediated G protein activation can facilitate both the binding
of [35S]-GTPgS, and the dissociation of existing [35S]-GTPgS
label from activated G proteins. Both of these eects are
utilized in the current study to show that G protein
stimulation through mu- and delta-receptor activation is
non-additive and that [35S]-GTPgS binding to G protein as a
result of mu- or delta-receptor activation can be caused to
dissociate by either a mu- or a delta-agonist. Taken together
these ®ndings strongly support the hypothesis that mu- and
delta-opioid receptors share a common G protein pool and
this provides an intracellular mechanism for interaction
between these two receptors.
Methods
Chemicals and drugs
[3H]-[D-Ala2, NMePhe4, Gly5-ol]-enkephalin ([3H]-DAMGO;
54.5 Ci/mmol; 2.02 TBq/mmol), [3H]-[D-Pen2,D-Pen5]enke-
phalin; ([3H]-DPDPE: 30 Ci/mmol; 1.67 TBq/mmol) and
[35S] - guanosine - 5' - O - (3 - thio) triphosphate ([35S] -GTPgS;
1250 Ci/mmol; 46.25 TBq/mmol) were purchased from Du
Pont NEN (Boston, MA, U.S.A.). The radioimmunoassay kit
for cyclic AMP was from Diagnostic Products Corp. (Los
Angeles, CA, U.S.A.). SNC80, (+)-4-[(R)-[(2S,5R)-2,5-di-
methyl - 4 - (2 - propenyl) - 1 - piperazinyl] - (3 -methoxyphenyl)-
methyl]-N,N-diethyl-benzamide was a kind gift from Dr K.C.
Rice, National Institutes of Health, Bethesda, MD, U.S.A.
CTAP (D-Phe-c[Cys-Tyr-D-Trp-Asp-Thr-Pen]-Thr-NH2) and
TIPP[c] (H-Tyr-Ticc-[CH2NH]Phe-Phe-OH) were provided
by the National Institute on Drug Abuse (Rockville, MD,
U.S.A.). DAMGO, GTPgS, GDP, 3-isobutyl-1-methyl-
xanthine (IBMX) and all other biochemicals were from the
Sigma Chemical Co. (St. Louis, MO, U.S.A.) and were of
analytical grade. Foetal bovine serum and all cell culture
media and additives were purchased from Gibco Life Sciences
(Gaithersberg, MD, U.S.A.).
Cell culture
SH-SY5Y cells and C6 rat glioma cells stably transfected with
a rat mu (C6(m)) or delta (C6(d)) opioid receptor (Lee et al.,
1999) were used. Cells were grown to con¯uence under 5%
CO2 in either Minimum Essential Medium (SH-SY5Y cells)
or Dulbecco's Modi®ed Eagle's Medium (DMEM) (C6 cells)
containing 10% foetal bovine serum. For subculture of stable
transfected C6 cells one ¯ask from each passage was grown in
the presence of 1 mg ml71 Geneticin. Cells used for
experiments were grown in the absence of Geneticin without
a signi®cant loss in receptor density. For the study of
tolerance, cells were grown in the presence of DAMGO
(1 mM) or SNC80 (1 mM) or vehicle for 18 h prior to harvest.
Compounds were added in a sterile water/DMSO vehicle
such that the ®nal DMSO concentration was 0.01%.
Membrane preparation
Cells were rinsed twice with ice-cold phosphate-buered
saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4,
pH 7.4), detached from dishes by incubation with lifting
buer (mM: glucose 5.6, KCl 5, HEPES 5, NaCl 137, EGTA
1, pH 7.4) and collected by centrifugation (5006g). The cells
were resuspended in ice-cold lysis buer (0.2 mM MgSO4,
0.38 mM KH2PO4, 0.61 mM Na2HPO4, pH 7.4) and homo-
genized using a glass-glass Dounce homogenizer. Crude
membranes were isolated by centrifugation for 20 min at
20,0006g. The resulting membrane pellets were resuspended
in 50 mM Tris-HCl buer (pH 7.4) and stored at 7808C in
500 ml aliquots containing 0.5 mg protein (Bradford, 1976).
All procedures were performed at 48C.
Ligand-binding assays
SH-SY5Y cell membranes (75 mg) were incubated for 2 h in a
shaking water bath at 258C with varying concentrations
(0.05 ± 25 nM) of [3H]-DAMGO or [3H]-DPDPE in 2 ml
50 mM Tris-HCl buer (pH 7.4) or GTPgS binding buer
(mM: Tris 50, NaCl 100, MgCl2 5, EDTA 1, dithiothreitol 1,
pH 7.4) containing 30 mM GDP. The reactions were
terminated by the addition of 2 ml ice-cold Tris-HCl buer.
The contents of the tubes were then rapidly vacuum-®ltered
through glass ®bre ®lters (Schleicher & Schuell no.32, Keene,
NH, U.S.A.) and the tubes and ®lters rinsed with ice-cold
3 ml Tris-HCl an additional three times. Radioactivity
retained by the ®lters was determined by liquid scintillation
counting. Non-speci®c binding was de®ned with 10 mM
naloxone.
Cyclic AMP assay
SH-SY5Y cells were grown in 24-well plates for 24 h to
con¯uency as described above. The culture medium was then
replaced with DMEM without foetal bovine serum, followed
by replacement of the media with DMEM at 378 containing
1.0 mM IBMX, 30 mM forskolin with or without appropriate
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opioid agonist. After 30 min at 378, the assay was stopped by
removing the assay medium and replacing with 1 ml ice cold
3% perchloric acid. After at least 30 min at 48, a 400 ml
aliquot was removed from each well, neutralized with 75 ml
2.5 M KHCO3 and centrifuged for 1 min at 15,0006g. A
radioimmunoassay kit was used to quantify accumulated
cyclic AMP in a 10 ml aliquot of the supernatant from each
sample. Inhibition of cyclic AMP formation was determined
as a per cent of forskolin-stimulated cyclic AMP accumula-
tion in the absence of opioid agonist.
[35S]GTPgS binding
Membranes (30 mg protein) of SH-SY5Y, C6(m) or C6(d) cells
were incubated with 50 pM [35S]GTPgS for 60 min at 258C, in
the absence or presence of varying concentrations of agonist,
in GTPgS binding buer (®nal concentration mM: Tris 50,
NaCl 100, MgCl2 5, EDTA 1, dithiothreitol 1, GDP 50 mM,
pH 7.4) in a ®nal assay volume of 400 ml. Reactions were
terminated by the addition of 2 ml ice-cold washing buer
(mM: Tris 50, NaCl 100, MgCl2 5, pH 7.4), followed by rapid
®ltration as above. The tubes and ®lters were rinsed three
times with 3 ml ice-cold washing buer and bound ligand
determined by scintillation counting.
[35S]GTPgS dissociation
SH-SY5Y cell membranes (1 mg protein) were incubated for
80 min at 258C with 80 pM [35S]-GTPgS in GTPgS binding
buer, in either the presence or absence of 1 mM DAMGO or
1 mM SNC80, in a total volume of 8 ml. An 800 ml sample of
the membrane suspension was removed and ®ltered (as
above) to determine maximal [35S]-GTPgS binding. Antago-
nist (TIPP[c], 3 mM or CTAP, 300 nM) or ddH2O in the
presence or absence of appropriate agonist was added 5 min
before 50 mM unlabelled GTPgS and eight6800 ml samples
were then removed at 1 ± 15 min intervals up to 58 min.
Samples were ®ltered and counted as described for
[35S]GTPgS association assays.
Data analysis
Graph Pad Prism (San Diego, CA, U.S.A.) was used to
perform linear and nonlinear regression analysis of the data.
Ligand saturation binding data were analysed using a one-
site saturation binding equation. Concentration response
curves for [35S]-GTPgS binding were ®tted to a sigmoidal
curve with a Hill coecient of unity. [35S]-GTPgS dissociation
experiments were ®t to a one-phase exponential decay curve.
Data are presented as mean+standard error of the mean or
as 95% con®dence intervals (C.I.) from at least three separate
experiments each performed in duplicate.
Results
Ligand binding
Saturation binding of the selective mu agonist [3H]-DAMGO
and selective delta agonist [3H]-DPDPE was measured in
membranes from SH-SY5Y cells. In Tris-HCl buer [3H]-
DAMGO bound to SH-SY5Y cell membranes with a Bmax of
600+60 fmol/mg protein and Kd of 0.4+0.1 nM and [3H]-
DPDPE aorded a Bmax of 280+20 fmol/mg protein and Kd
of 1.8+0.2 nM, indicating a 2 : 1 ratio of mu to delta
receptors. In GTPgS binding buer that contains NaCl
(100 mM) and 30 mM GDP the level of binding of both
ligands was considerably reduced. Thus, [3H]-DAMGO
bound with Kd of 8.3 nM and Bmax of 85+9 fmols/mg
protein and [3H]-DPDPE bound with Kd of 11.0+2.1 nM and
Bmax of 91+27 fmols/mg protein. The presence of the delta
antagonist TIPP[c] (10 nM) did not change the binding
parameters for [3H]-DAMGO (Kd=8.0+1.9 nM;
Bmax=90+4 fmol/mg protein).
Adenylyl cyclase
Cyclic AMP accumulation stimulated by forskolin was
reduced to 65.3+3.2% by 1 mM DAMGO and to
86.2+4.8% by 1 mM SNC80. The addition of SNC80 (1 mM)
and DAMGO (1 mM) together did not increase the level of
cyclic AMP inhibited by DAMGO alone (65.4+3.3%).
[35S]-GTPgS binding
Basal [35S]-GTPgS binding to membranes from SH-SY5Y
cells was 16.1+1.4 fmols/mg protein. DAMGO caused a
doubling of [35S]-GTPgS binding with an EC50 of 45 nM
(95% C.I., 30 ± 67 nM). The selective delta full agonist SNC80
aorded an EC50 of 32 nM (95% C.I., 11 ± 54 nM), but
produced only 57+5% of the maximal [35S]-GTPgS binding
stimulation seen with DAMGO (Figure 1).
To verify that DAMGO and SNC80 produced their eects
by selectively acting at mu and delta receptors respectively,
concentration-response curves were determined in the pres-
ence of the mu-selective antagonist CTAP (Pelton et al.,
1986) or the delta-selective antagonist TIPP[c] (Schiller et al.,
1993). Addition of 300 nM CTAP shifted the DAMGO
concentration-response curve 47 fold (Figure 2A), but
produced only a statistically insigni®cant 1.5 fold shift in
the SNC80 concentration-response curve (Figure 2B).
Conversely, 10 mM TIPP[c] completely blocked the eect
of SNC80 at concentrations up to 10 mM (Figure 2C) but
Figure 1 Stimulation of [35S]-GTPgS binding by DAMGO and
SNC80. SH-SY5Y membrane homogenates were incubated with
50 pM [35S]-GTPgS in the presence of DAMGO or SNC80 as
described in Methods. The data are expressed as [35S]-GTPgS binding
stimulation relative to the maximum eect produced by DAMGO.
Data represent means+s.e.mean from at least three experiments
carried out in duplicate.
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had no signi®cant eect (1.4 fold shift) on the concentration-
response curve for DAMGO (Figure 2D). The selectivity of
DAMGO and SNC80 for the mu and delta opioid receptors
respectively was con®rmed in membranes from C6 rat
glioma cells stably expressing cloned mu or delta opioid
receptors. In C6(m) cell membranes, DAMGO stimulated
[35S]-GTPgS binding with potency similar to that seen in SH-
SY5Y membranes (EC50=32 nM, 95% C.I., 13 ± 76 nM) but
SNC80 at concentrations up to 10 mM had no signi®cant
eect (9+9% of maximal DAMGO stimulation). Conver-
sely, in C6(d) cell membranes, SNC80 stimulated [35S]-
GTPgS binding with an EC50 of 18 nM (95% C.I., 6 ±
56 nM), but DAMGO had no appreciable eect at
concentrations up to 10 mM, producing only 4+1% of the
maximal SNC80 stimulation.
To test the hypothesis that mu and delta opioid receptors
share a common pool of G proteins, the additivity of G
protein activation by DAMGO and SNC80 in SH-SY5Y cell
membranes was measured. When maximally eective con-
centrations of DAMGO and SNC80 were combined, the level
of [35S]-GTPgS binding was not signi®cantly greater than that
produced by DAMGO alone (Figure 3).
[35S]-GTPgS dissociation
To further test the hypothesis that mu and delta receptors
access the same G proteins, the eect of receptor activation
on [35S]-GTPgS dissociation was measured. Membranes from
SH-SY5Y cells were incubated with [35S]-GTPgS and 1 mM
DAMGO to label mu-receptor associated G proteins.
Dissociation of the [35S]-GTPgS label was measured after
addition of a large excess of unlabelled GTPgS (Figure 4A);
the DAMGO was not removed. Continued mu receptor
activation resulted in rapid [35S]-GTPgS dissociation with a
t1/2 of 9+1 min, though only 58+6% of the DAMGO-
induced [35S]-GTPgS binding was dissociable. The dissocia-
tion time was markedly extended (t1/2=37+18 min) in the
presence of the mu antagonist CTAP (300 nM). When 1 mM
SNC80 was added in addition to CTAP, an increase in the
Figure 2 Eect of mu-(CTAP) and delta- (TIPPc) selective
antagonists on DAMGO and SNC80 concentration-response curves.
Concentration-response curves for [35S]-GTPgS binding were deter-
mined for DAMGO and SNC80 in the absence and presence of
antagonist, and expressed as % maximal stimulation. (A) 300 nM
CTAP produces a 1.68+0.14 log rightward shift in the DAMGO
concentration-response curve. (B) 300 nM CTAP has no signi®cant
eect (0.19+0.15 log rightward shift) on the SNC80 concentration-
response curve. (C) 10 mM TIPP[c] blocks G protein stimulation by
SNC80 at concentrations up to 10 mM. (D) 10 mM TIPP[c] has no
signi®cant eect (0.14+0.25 log leftward shift) on the DAMGO
concentration-response curve. Shown are means+s.e.mean from at
least three independent experiments carried out in duplicate.
Figure 3 Non-additivity of mu- and delta- mediated G protein
activation. Stimulation of [35S]-GTPgS binding by maximally eective
(10 mM) concentrations of DAMGO and SNC80 was measured.
SNC80 alone produced 50+4% of the eect aorded by 10 mM
DAMGO. When 10 mM SNC80 was combined with 10 mM DAMGO,
the total G protein activation totalled 108+4% of that produced by
DAMGO alone. Values are means+s.e.mean from three independent
experiments carried out in duplicate.
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[35S]-GTPgS dissociation rate was seen to give a t1/2 of
17+2 min, though the dissociation observed was slower than
that seen with DAMGO alone. Of the DAMGO-stimulated
[35S]-GTPgS binding, 45+2% was found to dissociate in the
presence of SNC80.
Delta-receptor coupled G proteins in SH-SY5Y cell
membranes were labelled with [35S]-GTPgS in the presence
of 1 mM SNC80. Dissociation of [35S]-GTPgS was measured
following addition of an excess of unlabelled GTPgS; the
SNC80 was not removed (Figure 4B). Continued delta
receptor activation resulted in rapid dissociation of [35S]-
GTPgS (t1/2=14+2 min). In contrast to DAMGO-stimulated
[35S]-GTPgS binding, almost all (88+7%) of SNC80-
stimulated [35S]-GTPgS binding was found to be reversible.
Blockade of the delta receptor with 3 mM TIPP[c] resulted in
a decreased [35S]-GTPgS dissociation rate (t1/2=34+6 min).
However, addition of 1 mM DAMGO increased the dissocia-
tion rate to a similar rate as seen in the presence of 1 mM
SNC80 alone (t1/2=11+1 min), with a maximal dissociation
of 77+5% of the bound [35S]-GTPgS. Neither DAMGO nor
SNC80 produced dissociation of agonist-unstimulated (basal)
[35S]-GTPgS binding (data not shown).
Tolerance
To determine whether cross-tolerance is exhibited between
mu and delta agonists in this system, SH-SY5Y cells were
treated for 18 h in the presence or absence of 1 mM DAMGO
or 1 mM SNC80 prior to harvesting and membrane
preparation. DAMGO-stimulated [35S]GTPgS binding in
membranes from cells treated chronically with DAMGO
was only 55+4% of that seen in control cells, but with no
signi®cant change in EC50. The EC50 value for DAMGO was
25 nM (95% C.I., 11 ± 54 nM) in membranes from chronic
DAMGO-treated cells versus 23 nM (95% C.I., 13 ± 38 nM) in
membranes from cells treated with vehicle only (Figure 5A).
The SNC80 concentration-response curve was not signi®-
cantly aected by 18 h DAMGO treatment. Thus, in
membranes from DAMGO-treated cells maximal [35S]-GTPgS
binding was equal to 97+5% of that seen in untreated cells
and there was no change in the EC50 (10 nM, 95% C.I., 7 ±
14 nM versus 9 nM, 95% C.I., 5 ± 17 nM in control mem-
branes; Figure 5B).
Chronic treatment of cells with SNC80 resulted in a
complete insensitivity of membranes to subsequent SNC80
administration at concentrations up to 10 mM (Figure 5C),
with no eect on the DAMGO concentration-response
curve (Figure 5D). Maximal DAMGO stimulation of [35S]-
GTPgS binding in membranes from chronic SNC80-treated
cells was equal to 99+8% of that seen in control cells,
with EC50 of 28 nM (95% C.I., 17 ± 45 nM) versus 29 nM
(95% C.I., 18 ± 46 nM) in membranes from cells treated
with vehicle alone.
Discussion
Mu and delta opioid receptors can activate the same
inhibitory G protein subtypes (Prather et al., 1994a;
Chakrabarti et al., 1995) although in SH-SY5Y human
neuroblastoma cells mu and delta receptors do show a
dierent preference for Ga subunits (Laugwitz et al., 1993).
The current study was designed to test the hypothesis that mu
and delta receptors share a common pool of G proteins and
that at full receptor occupancy the receptors compete for G
protein.
The mu-selective agonist DAMGO and the delta-selective
agonist SNC80 stimulated [35S]-GTPgS binding in a concen-
tration-dependent manner in SH-SY5Y cells. SNC80 pro-
duced 57+5% of the maximum eect seen with DAMGO,
consistent with the 1 : 2 ratio of total delta to mu receptors as
measured in Tris buer. In the presence of the more complex
buer containing Na+ ions and GDP the measured number
of mu and delta receptors was equivalent, but much reduced,
together with a reduction in ligand anity. This suggests the
total receptor number, rather than the number of receptors in
a particular anity state, governs the maximal level of [35S]-
GTPgS binding.
Figure 4 Agonist stimulation of [35S]-GTPgS dissociation. (A) SH-
SY5Y membranes were incubated with 80 pM [35S]-GTPgS and 1 mM
DAMGO to label mu-sensitive G proteins, as described in Methods.
At time zero, dissociation was initiated by the addition of 50 mM
unlabelled GTPgS in the absence or presence of 300 nM CTAP or
300 nM CTAP+1 mM SNC80. (B) Delta-sensitive G proteins were
labelled using 1 mM SNC80. To start dissociation, 50 mM unlabelled
GTPgS was added in the absence or presence of 3 mM TIPP[c], or
3 mM TIPP[c]+1 mM DAMGO. Shown are means+s.e.mean from
three independent experiments carried out in duplicate.
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When maximally eective concentrations of DAMGO and
SNC80 were combined, the eect produced was not
signi®cantly greater than that produced by DAMGO alone
determined either by stimulation of [35S]-GTPgS binding or
by the inhibition of cyclic AMP accumulation, indicating that
agonist-occupied mu and delta receptors activate common G
proteins. This conclusion was con®rmed by the ability of
agonists speci®c for either receptor to aord dissociation of
[35S]-GTPgS that had been caused to bind to G protein a-
subunits by either a mu or a delta agonist. Indeed, the ability
of both mu and delta agonists to cause dissociation suggests
the [35S]-GTPgS-occupied Ga subunit remains accessible to
both mu and delta receptors, such that both receptors can
access the C-terminus of the Ga subunit that is important for
receptor-G protein coupling (Conklin et al., 1993). This
conclusion is supported by studies demonstrating a persistent
membrane localization of Ga1 throughout the cycle of G
protein activation (Huang et al., 1999) and the ability of
receptor-G protein fusion proteins to interact with adenylyl
cyclase (Bertin et al., 1994; Milligan, 2000). Alternatively the
dissociation of bound [35S]-GTPgS could be through an
indirect mechanism. Gbg is known to promote the dissocia-
tion of [35S]-GTPgS from puri®ed Gao and Gai subunits and
this process is inhibited by Mg2+ (Sternweis & Robishaw,
1984; Higashijima et al., 1987). It is feasible that in native
membranes [35S]-GTPgS dissociation from Ga subunits can
be induced by Gbg, even in the presence of the level of Mg2+
(5 mM) used in the present assays. Thus, by agonist action in
the presence of a large excess of unlabelled GTPgS, GDP-
bound Gabg will be induced to bind unlabelled GTPgS,
releasing Gbg subunit that promotes [35S]-GTPgS dissociation
from Ga-[35S]-GTPgS labelled subunits (Breivogel et al.,
1998).
The simplest explanation for the ability of DAMGO and
SNC80 to activate the same G proteins would be if either or
both ligands lack receptor selectivity. However, this explana-
tion can be ruled out based on the eects of the selective
antagonists CTAP and TIPP[c] on agonist-induced [35S]-
GTPgS binding, and on the highly mu- selective action of
DAMGO and delta-selective action of SNC80 in membranes
from C6 cells expressing a single receptor type.
The ®nding that mu and delta receptors share G proteins
in SH-SY5Y cell membranes could indicate access of the
receptors to the complete inhibitory G protein pool, as for
example with Gi-coupled receptors in hamster adipocyte
membranes (Murayama & Ui, 1984). However, there is
evidence for compartmentalization of signalling in SH-SY5Y
cells with each receptor able to activate approximately four G
proteins (Remmers et al., 2000) and that the number of G
protein activated depends upon the receptor concentration.
The observation that maximal delta-agonist mediated G
protein activation was only half of that produced by agonist
occupation of the mu receptors indicates either that delta
receptors cannot access the entire G protein pool available to
mu receptors or that one or more species of mu receptor-
sensitive G proteins exist which are relatively insensitive to
delta receptor activation.
The ®ndings are also consistent with a model in which mu
and delta receptors are associated in a mu-delta complex
(Vaught et al., 1982) although the evidence for such a
complex has remained indirect (Traynor & Elliott, 1993).
More recently, opioid receptors have been shown to form
homo- (Cvejic & Devi, 1997), and hetero-oligomers (Jordan
& Devi, 1999; George et al., 2000; Gomes et al., 2000). The
ability of mu and delta receptors to share individual G
proteins in the current study may indicate that the receptors
are in close physical proximity to each other, and it is
tempting to speculate that these opioid receptors exist as
heterooligomers in SH-SY5Y cell membranes. Certainly, mu
Figure 5 Eect of chronic opioid treatment on [35S]-GTPgS
binding. SH-SY5Y cells were incubated for 18 h in the absence or
presence of 1 mM DAMGO (A and B) or 1 mM SNC80 (C and D)
prior to harvesting. Stimulation of [35S]-GTPgS binding in response
to subsequent DAMGO or SNC80 was then measured. Data are
presented as means+s.e.mean from three independent experiments
carried out in duplicate.
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and delta receptors form heterooligomers when co-expressed
in COS-7 cells and such heterooligomers have unique
properties (George et al., 2000). However, there is no
evidence for a new signalling entity composed of mu and
delta receptors in the SH-SY5Y cell membranes employed in
this study. Firstly, the EC50 for stimulation of [
35S]-GTPgS
binding by DAMGO or SNC80 is the same in these cells as
in C6 cells expressing the mu and delta opioid receptor
separately. Secondly, the delta antagonist TIPP[c] does not
alter the activation of [35S]-GTPgS binding via mu receptor
activation and the mu antagonist CTAP does not eect
activation of [35S]GTPgS binding via the delta receptor. This
contrasts with ®ndings that TIPP[c] increases the potency
and ecacy of DAMGO, and the mu antagonist CTOP
increases the potency and ecacy of the delta-agonist
Deltorphin II, to induce phosphorylation of p-42/44 MAP
kinase in SK-N-SH cells (Gomes et al., 2000). Finally, the
delta antagonist TIPP[c] does not alter the binding of the mu
agonist [3H]-DAMGO to membranes from SH-SY5Y cells,
an eect reported in both SK-N-SH cells and HEK-393 cells
expressing mu and delta opioid receptors and believed to be
due to the delta antagonist releasing the mu binding pocket
by disruption of the heterodimer (Gomes et al., 2001). Thus,
our results suggest that in human neuroblastoma SH-SY5Y
cells mu and delta receptors access the same G proteins
without necessarily forming hetero-complexes or a new
signalling entity.
The ability of mu and delta opioid receptors to activate the
same pool of G proteins could explain reported mu delta
interactions. For example, in certain in vivo systems the
potency and ecacy of morphine, but not higher ecacy
agonists such as DAMGO, is increased by sub-eective
concentrations of DPDPE or Leu-enkephalin (Vaught et al.,
1982; Heyman et al., 1989a; Sheldon et al., 1989; Jiang et al.,
1990). Since some cells do co-express both mu and delta
receptors (Ji et al., 1995) this may be caused by addition of
the stimulatory eects of mu and delta agonists on G protein
or by a `priming' of G protein by the delta agonists.
Presumably such interaction would also occur in the opposite
direction and so could contribute to the modulation of spinal
analgesia and the lack of delta-mediated respiratory depres-
sion in mu-receptor knock-out mice. However, the observa-
tion that the delta agonists Met-enkephalin and Met-
enkephalinamide inhibit morphine antinociception (Vaught
& Takemori, 1979; Vaught et al., 1982; Heyman et al., 1989b;
Jiang et al., 1990) is dicult to explain with this model.
Prolonged exposure of opioid receptors to agonist is
known to produce a state of tolerance which includes
uncoupling of receptor and G protein, receptor down-
regulation and compensatory changes in downstream eec-
tors. Although mu and delta receptors share G proteins in
SH-SY5Y membranes, tolerance was seen to be homologous
and therefore occurred at the receptor, rather than at the G
protein. Chronic DAMGO treatment of SH-SY5Y cells
results in a reduction in receptor number (Elliott et al.,
1997) but it can be inferred that the majority of G proteins
remained fully functional, since SNC80 still produced its full
G protein activation in the face of tolerance to DAMGO and
vice-versa. This is consistent with ®ndings that functional
coupling of the delta opioid receptor is not altered in mu-
receptor knockout mice (Matthes et al., 1998). Furthermore
the ®ndings agree with previous reports that opioid tolerance
is homologous in SH-SY5Y cells, both in terms of receptor
down-regulation (Zadina et al., 1994), and desensitization of
the adenylyl cyclase response (Prather et al., 1994b).
In SK-N-SH, the parent cell line of SH-SY5Y cells, which
express mu and delta receptors, mu and delta opioid receptor
down-regulation is also homologous (Baumhaker et al.,
1993). However, in SK-N-SH cells there is no evidence for
cross-talk at the level of G protein and each receptor appears
to activate a separate pool of G proteins (Shapiro et al.,
2000). When transfected into COS-7 cells mu and delta
receptors do share a common pool of G proteins and so
Shapiro et al. (2000) suggest the ®ndings are due to
dierences between transfected cell lines, where receptors
show promiscuous coupling, and cells which natively express
mu and delta opioid receptors. Our results with mu and delta
receptors endogenously expressed in SH-SY5Y cells suggest
dierences between this cell and its parent SK-N-SH and thus
do not support this conclusion. The results, however, do
support the broader concept that cellular organization is
important in governing which signal transduction pathways
are activated by a particular receptor and so varies across cell
types.
In conclusion, the data presented con®rm that although mu
and delta receptors may prefer particular Gi/Go subtypes
there is no absolute speci®city governed by receptor structure.
The ®ndings provide strong evidence for a common
activation of G protein by mu and delta opioid receptors in
SH-SY5Y human neuroblastoma cells that may play a role in
the pharmacology of mu and delta opioid receptors. More-
over the results are consistent with a compartmental
organization of mu receptors, delta receptors and G protein
for the control of receptor signalling.
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